Key points are not available for this paper at this time.
Successful development of future targeted therapies will require the flexibility to rapidly evaluate combination regimens involving new targeted agents in a single development program. The FDA has therefore developed draft guidance on drug co-development.
Woodcock et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: